R R

What Is Omnitrope?

Omnitrope is a prescription medication containing somatropin, a recombinant form of human growth hormone. It is used to treat growth hormone deficiency in adults and selected growth disorders in children. Pediatric indications include growth failure associated with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, being born small for gestational age without adequate catch-up growth, and idiopathic short stature. Omnitrope is administered through subcutaneous injections under the supervision of a healthcare professional experienced in growth disorders.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Omnitrope?

Omnitrope is a prescription medication containing somatropin, a recombinant form of human growth hormone. It is used to treat growth hormone deficiency in adults and selected growth disorders in children. Pediatric indications include growth failure associated with growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, being born small for gestational age without adequate catch-up growth, and idiopathic short stature. Omnitrope is administered through subcutaneous injections under the supervision of a healthcare professional experienced in growth disorders.

read more about omnitrope ...

Copy this HTML:

Copy HTML Copied!

How Does Omnitrope Work?

Omnitrope contains somatropin, which acts on growth hormone receptors in the body. It stimulates production of insulin-like growth factor 1, or IGF-1, which participates in bone growth, tissue development, and metabolism. In children with eligible growth disorders, somatropin can increase linear growth while growth plates remain open. In adults with confirmed growth hormone deficiency, it replaces inadequate hormone activity. Omnitrope does not treat every cause of short stature and should not be used for growth promotion in healthy individuals.

Who Can Receive Omnitrope Treatment?

Omnitrope is approved for adults with confirmed growth hormone deficiency and children with specified growth disorders. Pediatric treatment requires an evaluation of growth measurements, medical history, hormone testing, and the underlying diagnosis. Some indications involve genetic disorders or a documented failure of catch-up growth. Omnitrope is contraindicated in patients with active malignancy, certain acute critical illnesses, and closed growth plates when used for growth promotion. Children with Prader-Willi syndrome require assessment for severe obesity and respiratory problems before treatment.

How Is Omnitrope Administered?

Omnitrope is injected beneath the skin, generally once daily, with dosing individualized by diagnosis, body weight, growth response, and laboratory findings. Pediatric growth hormone deficiency treatment commonly uses a total weekly dose of 0.16 to 0.24 mg per kilogram divided into six or seven injections. Other pediatric indications and adult replacement therapy have different dosing ranges. Injection sites should be rotated to reduce tissue changes. Patients and caregivers must receive training for the prescribed pen, cartridge, or vial formulation.

What Are the Side Effects and Warnings of Omnitrope?

Possible side effects include injection-site reactions, headache, joint discomfort, muscle pain, and fluid retention. Serious risks include increased intracranial pressure, changes in glucose regulation, thyroid dysfunction, and slipped capital femoral epiphysis in growing children. Growth hormone treatment can also worsen scoliosis during rapid growth. Fatal complications have been reported in certain children with Prader-Willi syndrome and severe respiratory risk factors. Persistent headaches, vision changes, limping, or breathing problems require prompt evaluation.

Common Questions About Omnitrope

Is Omnitrope a growth hormone medication?

Yes. Omnitrope contains somatropin, a recombinant form of human growth hormone used for specific pediatric growth disorders and adult growth hormone deficiency.

How often is Omnitrope injected?

Omnitrope is generally administered by subcutaneous injection six or seven days per week. The dose depends on the diagnosis and individual response.

Can adults receive Omnitrope?

Yes. Omnitrope is approved for adults with confirmed growth hormone deficiency. It is not intended for routine anti-aging or performance enhancement.

Can Omnitrope affect eyesight?

Yes. Growth hormone therapy can increase intracranial pressure, causing headaches and visual changes. Eye examinations and medical assessment are recommended when these symptoms occur.

References

DailyMed - OMNITROPE (somatropin) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5. Date Accessed October 22, 2026.

Human Growth Hormone. Medical Subject Headings. https://www.ncbi.nlm.nih.gov/mesh/68019382. Date Accessed October 22, 2026.

Omnitrope. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope. Date Accessed October 22, 2026.

Somatropin. PubChem. https://pubchem.ncbi.nlm.nih.gov/substance/472423450. Date Accessed October 22, 2026.

Somatropin Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a622022.html. Date Accessed October 22, 2026.